Effects of treatments on gender differences in patients with localized muscle-invasive bladder cancer

Int Urol Nephrol. 2022 Aug;54(8):1845-1855. doi: 10.1007/s11255-022-03200-w. Epub 2022 May 24.

Abstract

Purpose: To explore the gender differences in survival under different treatments in localized muscle-invasive bladder cancer (MIBC), and to find clinical strategies to improve the poor prognosis of female with bladder cancer (BC).

Methods: Patients with localized MIBC were collected in the SEER database from 2010 to 2016 to analyze the gender differences in clinical characteristics. Propensity score matching was used to balance the effects of confounding factors. Kaplan-Meier method and Cox proportional hazards regression model were performed to compare the overall survival (OS) and cancer-specific survival (CSS) of patients between different treatment subgroups.

Results: The entire cohort included 13,272 T2N0M0 MIBC patients, with a male-to-female incidence of 3:1. Compared with male patients, females had a higher age of onset and more blacks. There were more female patients undergoing bladder-sparing surgery (BSS) alone, and the OS and CSS were worse than those in males. The gender difference showed statistical significance in the BSS group, but not in the radical cystectomy (RC) group.

Conclusion: The survival of localized MIBC patients can be affected by treatments. Multi-modality treatment and RC may improve the survival prognosis of female patients.

Keywords: Gender difference; Muscle-invasive bladder cancer; Survival; Treatment.

MeSH terms

  • Cystectomy / methods
  • Female
  • Humans
  • Male
  • Muscles
  • Neoplasm Invasiveness
  • Retrospective Studies
  • Sex Factors
  • Treatment Outcome
  • Urinary Bladder Neoplasms* / surgery